Syndrome of Inappropriate Antidiuretic Hormone Secretion Workup
- Author: Christie P Thomas, MBBS, FRCP, FASN, FAHA; Chief Editor: Vecihi Batuman, MD, FACP, FASN more...
Approach Considerations
In the absence of a single laboratory test to confirm the diagnosis, SIADH is best defined by the classic criteria introduced by Bartter and Schwartz in 1967, which remain valid today. They can be summarized as follows[20] :
- Hyponatremia with corresponding hypoosmolality
- Continued renal excretion of Na+
- Urine less than maximally dilute
- Absence of clinical evidence of volume depletion - Normal skin turgor, blood pressure within the reference range
- Absence of other causes of hyponatremia - Adrenal insufficiency (mineralocorticoid deficiency, glucocorticoid deficiency), hypothyroidism, cardiac failure, pituitary insufficiency, renal disease with salt wastage, hepatic disease, drugs that impair renal water excretion
- Correction of hyponatremia by fluid restriction
Hyponatremia (ie, serum Na+ < 135 mmol/L) with concomitant hypo-osmolality (serum osmolality < 280 mOsm/kg) and high urine osmolality is the hallmark of SIADH. However, these findings only indicate that ADH is present and acting on the distal nephron; it does not indicate if the ADH secretion is “inappropriate.” A good clinical examination is required to confirm that the hyponatremia is not the result of decreased effective intravascular volume from volume depletion or from states of volume excess such as congestive heart failure and cirrhosis for which the secretion of ADH is “appropriate.”
In SIADH, serum osmolality is generally lower than urine osmolality. In the setting of serum hypo-osmolality, ADH secretion is usually suppressed to allow the excess water to be excreted, thus moving the plasma osmolality toward normal. If ADH secretion is shut down completely, urine should have an osmolality of less than 100 mOsm. Therefore, urine osmolality of more than 100 mOsm in the context of plasma hypo-osmolality is sufficient to confirm ADH excess. Inappropriate water retention causes the dilutional hyponatremia.
Urine Na+ concentration in persons with SIADH is usually more than 40 mEq/L because, in SIADH, Na+ handling is not abnormal and the urine Na+ concentration reflects Na+ intake, which is generally more than 40 mEq/d (usually 50-100 mEq/d). However, the urine Na+ concentration in persons with SIADH can be modulated by dietary Na+ intake. Thus, on a low-Na+ diet, patients with SIADH may have a urine Na+ level of less than 40 mEq/L.
Laboratory Tests
Order the following tests to help in the diagnosis of SIADH:
- Serum Na+, potassium, chloride, and bicarbonate
- Plasma osmolality
- Serum creatinine
- Blood urea nitrogen
- Blood glucose
- Urine osmolality
- Serum uric acid
- Serum cortisol
- Thyroid-stimulating hormone
Serum osmolality
In persons with SIADH, the hyponatremia is associated with measured serum hypo-osmolality.
Serum Na
Hyponatremia (ie, serum Na+ < 135 mmol/L) is a defining feature of SIADH.
Serum bicarbonate
Serum bicarbonate remains within the reference range despite hypotonic expansion of body fluids in SIADH. This is postulated to be due to the movement of hydrogen ions into the cells and to increased hydrogen ion excretion by the renal tubules, both of which avert a dilutional fall in the serum bicarbonate concentration.
Serum potassium
Serum potassium concentration generally remains unchanged. Movement of potassium from the intracellular space to the extracellular space prevents dilutional hypokalemia. As hydrogen ions move intracellularly, they are exchanged for potassium in order to maintain electroneutrality.
If both hypokalemia and metabolic alkalosis are present, consider diuretic therapy or vomiting as the cause of hyponatremia. If hyperkalemia and metabolic acidosis coexist with hyponatremia, consider adrenal insufficiency and volume depletion leading to AKI.
Anion gap
The anion gap is reduced in SIADH secondary to equal dilution of serum Na+ and chloride, with unaffected bicarbonate (HCO3-). The anion gap is further decreased because the volume expansion probably reduces the tubular reabsorption of unmeasured anions, such as sulfate, phosphate, and urate.
Urinary Na excretion
In SIADH, urinary loss of Na+ continues despite significant hyponatremia. In these patients, as in healthy patients, urinary Na+ excretion is a reflection of Na+ intake and, therefore, usually is greater than 20 mmol/L. However, in the setting of Na+ restriction in patients with SIADH or in patients with volume depletion due to extrarenal losses, the urinary Na+ concentration may be very low.
Urinary osmolality
Patients with hyponatremia should turn off ADH and have a urine that is maximally dilute (ie, 50-100 mOsm/kg); however, in patients with SIADH, the urinary osmolality is usually submaximally dilute (ie, >100 mOsm/kg). One of the more common errors in recognizing SIADH is the failure to realize that the urine’s osmolality must be only inappropriately elevated and not necessarily greater than the corresponding serum osmolality.
BUN levels
Blood urea nitrogen (BUN) levels are unusually low, usually below 10 mg/dL. A low BUN level in SIADH occurs secondary to volume expansion because urea is distributed in total body water.
Hypouricemia
Hypouricemia (uric acid < 4 mg/dL) is frequently observed in patients with SIADH during the period of hyponatremia. An increase in fractional uric acid excretion (usually >9%) occurs as a result of volume expansion and a decrease in distal tubular reabsorption. In contrast, the serum uric acid is usually increased in hypovolemia. A decrease in serum uric acid concentration has been suggested as a screening procedure in patients with hyponatremia secondary to SIADH. However, hypouricemia lacks sensitivity and specificity for making the diagnosis of SIADH.
Glomerular filtration rate
The glomerular filtration rate (GFR) is increased as a result of extracellular water expansion induced by water retention.
ADH
The use of radioimmunoassay for ADH may provide supportive evidence for the diagnosis of SIADH. However, the values are not usually available quickly enough to assist in clinical decision making. Moreover, although the plasma ADH is typically elevated, this determination is not as important for the diagnosis of SIADH.
Volume Assessment
Hypovolemia
The patient should be assessed clinically to help rule out the presence of hypovolemia. Clues from the physical examination include hypotension with or without orthostasis, dry mucosae, cold peripheries, reduced skin turgor, and low central venous pressures (if central venous pressure or pulmonary capillary wedge pressure measurements are available).
In persons with hypovolemic hyponatremia, the urinary Na+ concentration is usually less than 20 mEq/L and the fractional excretion of Na+ is low. Thus, if the urinary Na+ concentration is less than 25 mEq/L, volume depletion from extrarenal volume loss should be excluded.
Volume depletion causes an appropriate (nonosmotic) secretion of ADH and leads to hyponatremia if hypotonic fluid is used to replace isotonic fluid losses. Typically, a volume-depleted person responds to thirst induced by volume depletion by drinking free water. Replacing isotonic losses (lost from the extracellular compartment) with water or hypotonic fluids makes a patient hyponatremic.
Hypovolemia can also be associated with a urine Na+ concentration more than 25 mEq/L if the source of volume loss is the kidney. Thus, diuretic use, mineralocorticoid deficiency, and salt-losing nephropathies can lead to hyponatremia with a high urine Na+ concentration.
Hypervolemia
The presence of peripheral edema with elevated jugular venous pressure, pulmonary rales, or ascites indicates increased volume, such as in heart failure or cirrhosis (with other signs of liver failure).
Euvolemia
In euvolemic states, before attributing the hyponatremia to SIADH, renal disease and endocrine disorders such thyroid, pituitary, and adrenal insufficiency should be excluded.
Imaging Studies
Chest radiographs
Chest radiographs may reveal an underlying pulmonary cause of SIADH.
CT or MRI scans
Computed tomography (CT) scanning or magnetic resonance imaging (MRI) of the head may be appropriate in selected cases. The study may show evidence of cerebral edema (eg, narrowing of the ventricles), a complication of SIADH, or may identify a CNS disorder responsible for SIADH (eg, brain tumor). CT scanning or MRI can also help rule out other potential causes of a change in neurologic status.
Verbalis JG, Berl T. Disorders of water balance. In: Brenner BM. Brenner & Rector's The Kidney. Vol 1. 8th ed. Saunders; 2007:459-491.
Elhassan EA, Schrier RW. Hyponatremia: diagnosis, complications, and management including V2 receptor antagonists. Curr Opin Nephrol Hypertens. Mar 2011;20(2):161-8. [Medline].
Kohen I, Voelker S, Manu P. Antipsychotic-induced hyponatremia: case report and literature review. Am J Ther. Sep-Oct 2008;15(5):492-4. [Medline].
Vitting KE, Gardenswartz MH, Zabetakis PM, et al. Frequency of hyponatremia and nonosmolar vasopressin release in the acquired immunodeficiency syndrome. JAMA. Feb 16 1990;263(7):973-8. [Medline].
Hoorn EJ, Lindemans J, Zietse R. Development of severe hyponatraemia in hospitalized patients: treatment-related risk factors and inadequate management. Nephrol Dial Transplant. Jan 2006;21(1):70-6. [Medline].
Schrier RW. Body water homeostasis: clinical disorders of urinary dilution and concentration. J Am Soc Nephrol. Jul 2006;17(7):1820-32. [Medline].
Stelfox HT, Ahmed SB, Khandwala F, Zygun D, Shahpori R, Laupland K. The epidemiology of intensive care unit-acquired hyponatraemia and hypernatraemia in medical-surgical intensive care units. Crit Care. 2008;12(6):R162. [Medline]. [Full Text].
Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. Am J Med. Jul 2006;119(7 Suppl 1):S30-5. [Medline].
Ayus JC, Varon J, Arieff AI. Hyponatremia, cerebral edema, and noncardiogenic pulmonary edema in marathon runners. Ann Intern Med. May 2 2000;132(9):711-4. [Medline].
Kumar S, Fowler M, Gonzalez-Toledo E, Jaffe SL. Central pontine myelinolysis, an update. Neurol Res. Apr 2006;28(3):360-6. [Medline].
Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med. May 17 2007;356(20):2064-72. [Medline].
Renneboog B, Musch W, Vandemergel X, Manto MU, Decaux G. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med. Jan 2006;119(1):71.e1-8. [Medline].
Clayton JA, Le Jeune IR, Hall IP. Severe hyponatraemia in medical in-patients: aetiology, assessment and outcome. QJM. Aug 2006;99(8):505-11. [Medline].
Decaux G. Is asymptomatic hyponatremia really asymptomatic?. Am J Med. Jul 2006;119(7 Suppl 1):S79-82. [Medline].
Hew-Butler T, Noakes TD, Siegel AJ. Practical management of exercise-associated hyponatremic encephalopathy: the sodium paradox of non-osmotic vasopressin secretion. Clin J Sport Med. Jul 2008;18(4):350-4. [Medline].
Sterns RH, Silver SM. Cerebral salt wasting versus SIADH: what difference?. J Am Soc Nephrol. Feb 2008;19(2):194-6. [Medline].
Yee AH, Burns JD, Wijdicks EF. Cerebral salt wasting: pathophysiology, diagnosis, and treatment. Neurosurg Clin N Am. Apr 2010;21(2):339-52. [Medline].
Tian W, Fu Y, Garcia-Elias A, et al. A loss-of-function nonsynonymous polymorphism in the osmoregulatory TRPV4 gene is associated with human hyponatremia. Proc Natl Acad Sci U S A. Aug 18 2009;106(33):14034-9. [Medline]. [Full Text].
Feldman BJ, Rosenthal SM, Vargas GA, et al. Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med. May 5 2005;352(18):1884-90. [Medline].
Bartter FC, Schwartz WB. The syndrome of inappropriate secretion of antidiuretic hormone. Am J Med. May 1967;42(5):790-806. [Medline].
Zeltser D, Rosansky S, van Rensburg H, Verbalis JG, Smith N. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol. 2007;27(5):447-57. [Medline].
Decker BC. Disorders of Water Excess: Hyponatremia. In: Dale DC, Federman DD, eds. ACP Medicine. Vol 1. BC Decker; 2007.
Nemerovski C, Hutchinson DJ. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review. Clin Ther. Jun 2010;32(6):1015-32. [Medline].
[Best Evidence] Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. Nov 16 2006;355(20):2099-112. [Medline].
Berl T, Quittnat-Pelletier F, Verbalis JG, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol. Apr 2010;21(4):705-12. [Medline]. [Full Text].
Gross P. Treatment of hyponatremia. Intern Med. 2008;47(10):885-91. [Medline].
Print
